Market News & Trends
Lonza Expands Particle Engineering Assets to Advance Complex Molecules
Lonza reecently announced additional investments in its global particle engineering network for expanded capacity and specialized capabilities. Jet milling and spray dry processing for development…
Cambrex Increases Flexible Manufacturing Capacity
Cambrex, the leading small molecule company providing drug substance, drug product, and analytical services across the entire drug lifecycle, recently announced it is investing $3.6…
Geron Receives Positive Opinion from the EMA Committee for Orphan Medicinal Products
Geron Corporation recently announced the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opinion on the company’s application for orphan…
MediciNova Announces Opening of IND for MN-166 for Prevention of Acute Respiratory Distress Syndrome in Patients With COVID-19
MediciNova, Inc. recently announced that the Investigational New Drug Application (IND) for MN-166 (ibudilast) for prevention of Acute Respiratory Distress Syndrome (ARDS) has been accepted…
Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42 Million
Avadel Pharmaceuticals plc recently announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz, Vazculep,…
FDA Approves First & Only Oral Somatostatin Analog for Acromegaly
Chiasma, Inc. recently announced the US FDA approved MYCAPSSA (octreotide) capsules for long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment…
Artelo Biosciences Expands Stony Brook Commercial License Agreement for Development of Lead Cancer, Pain & Inflammation Compounds
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today announced that it has expanded…
Intra-Cellular Therapies Announces Positive Top-line Results from Phase 1/2 Study
Intra-Cellular Therapies, Inc. recently announced topline results from Study ITI-214-104, a Phase 1/2 translational study of single ascending doses of ITI-214, a novel, selective phosphodiesterase-1…
Aptose Announces FDA Allowance of IND for Phase 1a/b Study
Aptose Biosciences Inc. recently announced the US FDA completed its review of the company’s Investigational New Drug (IND) application and has granted IND allowance for…
Oncology Venture Signs Agreement to Out-License Two Pipeline Assets
Oncology Venture A/S (OV) recently announced it has signed a definitive agreement out-licensing two clinical pipeline assets, LiPlaCis and 2X-111, to Smerud Medical Research International…